Narrative Review of Drug-Associated Nail Toxicities in Oncologic Patients
Keywords:
nail toxicity, nail changes, chemotherapy, targeted treatment, immune checkpoint inhibitorsAbstract
Introduction Nail toxicity represents one of the most common cutaneous adverse effects of both classic chemotherapeutic agents and new oncologic drugs, including targeted treatments and immunotherapy.
Objectives We aimed to provide a comprehensive literature review of nail toxicities derived from conventional chemotherapeutic agents, targeted therapies (EGFR inhibitors, multikinase inhibitors, BRAF and MEK inhibitors) and immune checkpoint inhibitors (ICIs), including clinical presentation, implicated drugs and approaches for prevention and management.
Methods Retrieved literature from PubMed registry database was reviewed to include all articles published up to May 2021 relevant to the clinical presentation, diagnosis, incidence, prevention, and treatment of oncologic treatment-induced nail toxicity. The was searched for relevant studies.
Results A wide spectrum of nail toxicities is associated with both, conventional and newer anticancer agents. The frequency of nail involvement, especially with immunotherapy and new targeted agents remains unknown and patients with different cancer types receiving different regimens may develop the same nail disorder, whereas patients with the same type of cancer under the same chemotherapeutic treatment may develop different types of nail alterations. The underlying mechanisms of the varying individual susceptibility and the diverse nail responses to various anticancer treatments need further investigation.
Conclusion Early recognition and treatment of nail toxicities can minimize their impact, allowing better adherence to conventional and newer oncologic treatments. Dermatologists, oncologists and other implicated physicians should be aware of these burdensome adverse effects in order to guide management and prevent impairment of patients’ quality of life.
References
Pavey R, Kambil S, Bhat R. Dermatological adverse reactions to cancer chemotherapy. Indian J Dermatol Venereol Leprol. 2015;81(4):434.
Piraccini BM, Tosti A. Drug-induced nail disorders. Incidence, management and prognosis. Drug Saf. 1999;21(3):187–201.
Hinds G, Thomas VD. Malignancy and Cancer Treatment-Related Hair and Nail Changes. Dermatol Clin. 2008;26(1):59–68.
Saraswat N, Sood A, Verma R, Kumar D, Kumar S. Nail changes induced by chemotherapeutic agents. Indian J Dermatol [Internet]. 2020 May 1 [cited 2021 Apr 18];65(3):193. Available from: http://www.e-ijd.org/text.asp?2020/65/3/193/282451
Daniel CR, Scher RK. Nail changes secondary to systemic drugs or ingestants. J Am Acad Dermatol. 1984;10(2):250–8.
Chen W, Yu YS, Liu YH, Sheen JM, Hsiao CC. Nail changes associated with chemotherapy in children. J Eur Acad Dermatology Venereol. 2007;21(2):186–90.
Piraccini BM, Iorizzo M, Starace M, Tosti A. Drug-induced Nail Diseases. Dermatol Clin. 2006;24(3):387–91.
Piraccini BM, Iorizzo M. Drug Reactions Affecting the Nail Unit: Diagnosis and Management. Dermatol Clin. 2007;25(2):215–21.
Piraccini BM, Iorizzo M, Antonucci A, Tosti A. Drug-induced nail abnormalities. Expert Opin Drug Saf. 2004;3(1):57–65.
Uyttendaele H, Geyer A, Scher RK. Drugs and nails. J Eur Acad Dermatology Venereol. 2004;18(2):124–5.
Kirby JS MC. Chemotherapy Principles An In-depth Discussion of the Techniques and Its Role in Cancer Treatment. Intralesional Chemother nonmelanoma Ski cancer A Pract Rev. 2010;
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: Part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol [Internet]. 2014;71(2):203.e1-203.e12. Available from: http://dx.doi.org/10.1016/j.jaad.2014.04.014
Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol. 2008;58(4):545–70.
Dasanu CA, Wiernik PH, Vaillant J, Alexandrescu DT. A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer. Skinmed. 2007;6(2):95–6.
Malet‐Martino M, Martino R. Clinical Studies of Three Oral Prodrugs of 5‐Fluorouracil (Capecitabine, UFT, S‐1): A Review. Vol. 7, The Oncologist. 2002. p. 288–323.
Valks R, Garcia-Diez A, Fernandez-Herrera J. Mucocutaneous reactions to chemotherapy [3]. J Am Acad Dermatol. 2000;42(4):699.
Yamamoto T. Bleomycin and the skin. Br J Dermatol. 2006;155(5):869–75.
Turan Erkek E, Karaali CN, Yılmaz G, Gültürk E. Bleomycin-Induced Flagellate Dermatitis. Turkish J Haematol Off J Turkish Soc Haematol. 2019;36(2):138–40.
Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643–55.
Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994;344(8932):1267–72.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369(18):1691–703.
Sibaud V, Leboeuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatology. 2016;26(5):427–43.
Visual Observations. Science (80- ). 2011;37:2010–1.
Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol [Internet]. 2014;71(4):787–94. Available from: http://dx.doi.org/10.1016/j.jaad.2014.03.019
Scotté F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23(19):4424–9.
Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, et al. Taxane-induced nail changes: Incidence, clinical presentation and outcome. Ann Oncol. 2003;14(2):333–7.
Matsumoto K, Hino C, Fukuda K, Hamamoto M, Tanioka M, Hirokaga K, et al. Prospective Study of Ice Gel Pack as Less Expensive Alternative for Prevention of Skin and Nail Toxicity in Patients with Breast Cancer Receiving Docetaxel. 2009;1114–1114.
Can G, Aydiner A, Cavdar I. Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. Eur J Oncol Nurs [Internet]. 2012;16(3):270–5. Available from: http://dx.doi.org/10.1016/j.ejon.2011.06.007
Winther D, Saunte DM, Knap M, Haahr V, Jensen AB. Nail changes due to docetaxel - A neglected side effect and nuisance for the patient. Support Care Cancer. 2007;15(10):1191–7.
Cecco S, Aliberti M, Baldo P, Giacomin E, Leone R. Safety and efficacy evaluation of albumin-bound paclitaxel. Expert Opin Drug Saf. 2014;13(4):511–20.
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol. 2012;30(17):2055–62.
Ko YJ, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: A single group, multicentre, phase 2 study. Lancet Oncol [Internet]. 2013;14(8):769–76. Available from: http://dx.doi.org/10.1016/S1470-2045(13)70162-1
Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: Efficacy, safety, and approval. Onco Targets Ther. 2011;4:123–36.
Schepisi G, Conteduca V, Lolli C, Medri M, De Giorgi U. Taxane-related nail toxicity. Lancet Oncol [Internet]. 2015;16(7):e310–1. Available from: http://dx.doi.org/10.1016/S1470-2045(15)00019-4
Capriotti K, Capriotti JA, Lessin S, Wu S, Goldfarb S, Belum VR, et al. The risk of nail changes with taxane chemotherapy: A systematic review of the literature and meta-analysis. Br J Dermatol. 2015;173(3):842–5.
Sanmartín O, Beato C, Suh-Oh HJ, Aragón I, España A, Majem M, et al. Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Actas Dermosifiliogr. 2019;110(6):448–59.
Rubin AI, Jellinek NJ, Ralph Daniel C, Scher RK. Scher and Daniel’s nails: Diagnosis, surgery, therapy: Fourth edition. Scher Daniel’s Nails Diagnosis, Surgery, Ther Fourth Ed. 2018;1–665.
Baran & Dawber’s Diseases of the Nails and their Management. Vol. 1, Journal of Cosmetic Dermatology. 2002. 103–103 p.
Eng HT, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother. 2009;43(10):1658–66.
Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–95.
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol [Internet]. 2014;71(2):217.e1-217.e11. Available from: http://dx.doi.org/10.1016/j.jaad.2014.04.013
Apalla Z, Papageorgiou C, Lallas A, Delli F, Fotiadou C, Kemanetzi C, et al. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review. Dermatol Pract Concept. 2021;11(1):e2021155.
Acad Dermatol Venereol - 2021 - Apalla - European recommendations for management of immune checkpoint inhibitors‐derived.pdf.
Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254–63.
Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol [Internet]. 2018;19(3):345–61. Available from: https://doi.org/10.1007/s40257-017-0336-3
Gilbar P, Hain A, Peereboom Veta-Marie VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract. 2009;15(3):143–55.
Piraccini BM, Alessandrini A. Drug-related nail disease. Clin Dermatol [Internet]. 2013;31(5):618–26. Available from: http://dx.doi.org/10.1016/j.clindermatol.2013.06.013
Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol [Internet]. 2015;16(4):e181–9. Available from: http://dx.doi.org/10.1016/S1470-2045(14)71133-7
Sibaud V, Fricain JC, Baran R, Robert C. Pigmentary disorders induced by anticancer agents. Part I: Chemotherapy. Ann Dermatol Venereol. 2013;140(3):183–96.
Harrison BM, Wood CBS. Cyclophosphamide and Pigmentation. Br Med J. 1972;2(5809):352.
SHAH PC, RAO KRP, PATEL AR. Cyclophosphamide induced nail pigmentation. Br J Dermatol. 1978;98(6):675–80.
Adam BA. Cyclophosphamide nail pigmentation. Singapore Med J. 1981;22(1):35–7.
Prabodh S, Rao KRP, Ashok P. Cyclophosphamide-induced nail pigmentation. Br J Haematol. 2002;117(1):2.
Dave S, Thappa DM. Peculiar pattern of nail pigmentation following cyclophosphamide therapy. Dermatol Online J. 2003;9(3):148–51.
Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, et al. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995;13(12):2886–94.
Du A, Vivier D. British Journal of Dermatology 2002; 146: 705–718. 2002;705–18.
Mourad YA, Matta-Muallem M, Shamseddine A. Nail toxicity related to taxanes. Dermatol Online J. 2003;9(3):152–4.
Hardin J, Haber RM. Onychomadesis: Literature review. Br J Dermatol. 2015;172(3):592–6.
Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS. Onycholysis as a complication of systemic chemotherapy. Cancer. 2000;88(10):2367–71.
Maino KL, Norwood C, Stashower ME. Onycholysis with the appearance of a “sunset” secondary to capecitabine. Cutis. 2003;72(3):234–6.
Kochupillai V, Prabhu M, Bhide NK. Cancer Chemotherapy and Nail Loss (Onychomadesis) / Meningeal Relapse in Acute Promyelocytic Leukaemia. Acta Haematol. 1983;70(2):137–137.
Ceyhan AM, Yildirim M, Bircan HA, Karayigit DZ. Transverse leukonychia (Mees’ lines) associated with docetaxel. J Dermatol. 2010;37(2):188–9.
Parakh A, Kocchar AM. Chemotherapy induced transverse leukonychia (Mees’ lines). Indian Pediatr. 2007;44(11):865.
Mirfazaelian H, Namazi MR, Daneshbod Y. Mees’ lines. ScientificWorldJournal. 2011;11:267–8.
Kumar S, Diwan S, Dekate M, Goyal S. Mees’ line following chemotherapy. Our Dermatology Online. 2013;4(3):382–382.
Shelley WB, Humphrey GB. Transverse leukonychia (mees’ lines) due to daunorubicin chemotherapy. Pediatr Dermatol. 1997;14(2):144–5.
Alzahrani MF, AlJasser MI. Nail Changes during Chemotherapy. N Engl J Med. 2018;379(16):1561–1561.
Dasanu CA, Vaillant JG, Alexandrescu DT. Distinct patterns of chromonychia, Beau’s lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma. Dermatol Online J. 2006;12(6):5–7.
Scotté F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112(7):1625–31.
Mackay-Wiggan J, Nair KG, Halasz CLG. Onycholysis associated with paclitaxel. Cutis. 2003;71(3):229–32.
Ghetti E, Piraccini BM, Tosti A. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). J Eur Acad Dermatology Venereol. 2003;17(4):459–60.
Link CJ, Sarosy GA, Kohn EC, Christian MC, Davis P, Adamo DO, et al. Cutaneous manifestations of taxol® therapy. Invest New Drugs. 1995;13(3):261–3.
Wasner G, Hilpert F, Baron R, Pfisterer J. Clinical picture: Nail changes secondary to docetaxel. Lancet. 2001;357(9260):910.
Shemer A, Daniel CR. Common nail disorders. Clin Dermatol. 2013;31(5):578–86.
Boucher KW, Davidson K, Mirakhur B, Goldberg J, Heymann WR. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol. 2002;47(4):632–3.
Nakano J, Nakamura M. Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor [5]. J Dermatol. 2003;30(3):261–2.
Huang KL, Lin KY, Huang TW, Loh EW, Hua YM, Su HC, et al. Prophylactic management for taxane-induced nail toxicity: A systematic review and meta-analysis. Eur J Cancer Care (Engl). 2019;28(5):1–10.
Chanez J-F. The Neurogenic Component of Cutaneous Toxicities Induced by Chemotherapy—New Solutions. Oncol Hematol Rev. 2010;06:17.
Dawid-Pać R. Medicinal plants used in treatment of inflammatory skin diseases. Postep Dermatologii i Alergol. 2013;30(3):170–7.
Man MQ, Hupe M, Sun R, Man G, Mauro TM, Elias PM. Topical apigenin alleviates cutaneous inflammation in murine models. Evidence-based Complement Altern Med. 2012;2012.
Wollina U, Abdel-Naser MB. Drug reactions affecting hair and nails. Clin Dermatol [Internet]. 2020;38(6):693–701. Available from: https://doi.org/10.1016/j.clindermatol.2020.06.009
Published
Issue
Section
License
Copyright (c) 2022 Anastasia Emvalomati, Valentina Oflidou, Chryssoula Papageorgiou, Christina Kemanetzi, Maria Giannouli, Evangelia Kalloniati, Konstantinos Efthymiadis, Chrysanthi Koukoutzeli, Eleni Timotheadou, Anastasia Trigoni, Aikaterini Patsastsi, Elizabeth Lazaridou, Zoe Apalla, Myrto Trakatelli
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
